Advertisement

Neurocritical Care

, Volume 13, Issue 2, pp 286–294 | Cite as

Continuous Renal Replacement Therapies: A Brief Primer for the Neurointensivist

  • Pritesh Patel
  • Veena Nandwani
  • Paul J. McCarthy
  • Steven A. Conrad
  • L. Keith Scott
Review Article

Abstract

Continuous renal replacement therapy (CRRT) is a renal replacement modality that is often used in the ICU setting, including the neuro-ICU. This form of renal replacement therapy has been used classically for acute renal failure in patients with hemodynamic compromise, but is gaining acceptance as a method to control vascular and extra-vascular volume and mediate cytokines in non-renal diseases. Although these uses are briefly discussed, this review concentrates on the different forms of continuous renal replacement, mainly focusing on the technology of convective versus diffusive modalities and briefly on filter technology. There is also discussion on the various anticoagulation regimes used in CRRT including data on performing CRRT without anticoagulation. This review is not meant to be a discussion on the pros and cons of CRRT versus intermittent dialysis, but rather a primer on the technology of CRRT and how this therapy may affect general care of the ICU patient.

Keywords

CRRT CVVH CVVHDF Diffusive clearance Convective clearance 

References

  1. 1.
    Litmathe J, Kurt M, Feindt P, Gams E, Boeken U. Predictors and outcome of ICU readmission after cardiac surgery. Thorac Cardiovasc Surg. 2009;57(7):391–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Andrikos E, Tseke P, Balafa O, Cruz DN, Tsinta A, Androulaki M, Pappas M, Ronco C. Epidemiology of acute renal failure in ICUs: a multi-center prospective study. Blood Purif. 2009;28(3):239–44.Google Scholar
  3. 3.
    Charbonney E, Saudan P, Triverio PA, Quinn K, Mentha G, Martin PY. Prognosis of acute kidney injury requiring renal replacement therapy in solid organ transplanted patients. Transpl Int. 2009.Google Scholar
  4. 4.
    Cislaghi F, Condemi AM, Corona A. Predictors of prolonged mechanical ventilation in a cohort of 5123 cardiac surgical patients. Eur J Anaesthesiol. 2009;26(5):396–403.CrossRefPubMedGoogle Scholar
  5. 5.
    Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten HM, Ronco C, Kellum JA. Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury. J Crit Care. 2009;24(1):129–40.CrossRefPubMedGoogle Scholar
  6. 6.
    Zarbock A, Singbartl K, Kellum JA. Evidence-based renal replacement therapy for acute kidney injury. Minerva Anestesiol. 2009;75(3):135–9.PubMedGoogle Scholar
  7. 7.
    Lins RL, et al. Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomized clinical trial. Nephrol Dial Transplant. 2009;24(2):512–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Vege SS, Gardner TB, Chari ST, Munukuti P, Pearson RK, Clain JE, Petersen BT, Baron TH, Farnell MB, Sarr MG. Low mortality and high morbidity in severe acute pancreatitis without organ failure: a case for revising the Atlanta classification to include “moderately severe acute pancreatitis”. Am J Gastroenterol. 2009;104(3):710–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Ronco C, Bellomo R, Ricci Z. Continuous renal replacement therapy in critically ill patients. Nephrol Dial Transplant. 2001;16(Suppl 5):67–72.PubMedGoogle Scholar
  10. 10.
    Meyer MM. Renal replacement therapies. Crit Care Clin. 2000;16(1):29–58.CrossRefPubMedGoogle Scholar
  11. 11.
    Ronco C, Bellomo R, Kellum JA. Continuous renal replacement therapy: opinions and evidence. Adv Ren Replace Ther. 2002;9(4):229–44.CrossRefPubMedGoogle Scholar
  12. 12.
    Subach RA, Marx MA. Drug dosing in acute renal failure: the role of renal replacement therapy in altering drug pharmacokinetics. Adv Ren Replace Ther. 1998;5(2):141–7.PubMedGoogle Scholar
  13. 13.
    Veltri MA, Neu AM, Fivush BA, Parekh RS, Furth SL. Drug dosing during intermittent hemodialysis and continuous renal replacement therapy: special considerations in pediatric patients. Paediatr Drugs. 2004;6(1):45–65.CrossRefPubMedGoogle Scholar
  14. 14.
    Böhler J, Donauer J, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int Suppl. 1999;56(72):S24–8.Google Scholar
  15. 15.
    Joy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother. 1998;32(3):362–75.CrossRefPubMedGoogle Scholar
  16. 16.
    Li AM, Gomersall CD, Choi G, Tian Q, Joynt GM, Lipman J. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J Antimicrob Chemother. 2009;64(5):929–37.CrossRefPubMedGoogle Scholar
  17. 17.
    Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet. 2007;46(12):997–1038.CrossRefPubMedGoogle Scholar
  18. 18.
    Bellomo R, Ronco C. How to feed patients with renal dysfunction. Curr Opin Crit Care. 2000;6(4):239–46.CrossRefPubMedGoogle Scholar
  19. 19.
    Story DA, Ronco C, Bellomo R. Trace element and vitamin concentrations and losses in critically ill patients treated with continuous venovenous hemofiltration. Crit Care Med. 1999;27(1):220–3.CrossRefPubMedGoogle Scholar
  20. 20.
    Arzuaga A, et al. Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficient. Blood Purif. 2006;24(4):347–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Ronco C. Continuous renal replacement therapies for the treatment of acute renal failure in intensive care patients. Clin Nephrol. 1993;40(4):187–98.PubMedGoogle Scholar
  22. 22.
    Manns M, Sigler MH, Teehan BP. Continuous renal replacement therapies: an update. Am J Kidney Dis. 1998;32(2):185–207.CrossRefPubMedGoogle Scholar
  23. 23.
    Davenport A. The management of renal failure in patients at risk of cerebral edema/hypoxia. New Horiz. 1995;3(4):717–24.PubMedGoogle Scholar
  24. 24.
    Fletcher JJ, Bergman K, Feucht EC, Blostein P. Continuous renal replacement therapy for refractory intracranial hypertension. Neurocrit Care. 2009;11(1):101–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Yu C, Liu ZH, Chen ZH, Gong DH, Ji DX, Li LS. Improvement of monocyte function and immune homeostasis by high volume continuous venovenous hemofiltration in patients with severe acute pancreatitis. Int J Artif Organs. 2008;31(10):882–90.PubMedGoogle Scholar
  26. 26.
    Fortenberry JD, Paden ML. Extracorporeal therapies in the treatment of sepsis: experience and promise. Semin Pediatr Infect Dis. 2006;17(2):72–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Peng Y, Yuan Z, Li H. Removal of inflammatory cytokines and endotoxin by veno-venous continuous renal replacement therapy for burned patients with sepsis. Burns. 2005;31(5):623–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Druml W. Metabolic aspects of continuous renal replacement therapies. Kidney Int Suppl. 1999;(72):S56–61.Google Scholar
  29. 29.
    Ronco C, et al. Management of fluid balance in CRRT: a technical approach. Int J Artif Organs. 2005;28(8):765–76.PubMedGoogle Scholar
  30. 30.
    Davenport A. Continuous renal replacement therapy for liver disease. Hemodial Int. 2003;7(4):348–52.CrossRefPubMedGoogle Scholar
  31. 31.
    Clark WR, Mueller BA, Kraus MA, Macias WL. Extracorporeal therapy requirements for patients with acute renal failure. J Am Soc Nephrol. 1997;8(5):804–12.PubMedGoogle Scholar
  32. 32.
    Soni SS, Nagarik AP, Adikey GK, Raman A. Using continuous renal replacement therapy to manage patients of shock and acute renal failure. J Emerg Trauma Shock. 2009;2(1):19–22.CrossRefPubMedGoogle Scholar
  33. 33.
    Joannidis M. Continuous renal replacement therapy in sepsis and multisystem organ failure. Semin Dial. 2009;22(2):160–4.CrossRefPubMedGoogle Scholar
  34. 34.
    Bouchard J, Mehta RL. Acid-base disturbances in the intensive care unit: current issues and the use of continuous renal replacement therapy as a customized treatment tool. Int J Artif Organs. 2008;31(1):6–14.PubMedGoogle Scholar
  35. 35.
    Bellomo R, Ronco C. Blood purification in the intensive care unit: evolving concepts. World J Surg. 2001;25(5):677–83.CrossRefPubMedGoogle Scholar
  36. 36.
    Dunham CM. Clinical impact of continuous renal replacement therapy on multiple organ failure. World J Surg. 2001;25(5):669–76.CrossRefPubMedGoogle Scholar
  37. 37.
    Wei Q, Baihai S, Ping F, Xiaolei C, Jing L, Rong Z. Successful treatment of crush syndrome complicated with multiple organ dysfunction syndrome using hybrid continuous renal replacement therapy. Blood Purif. 2009;28(3):175–80.CrossRefPubMedGoogle Scholar
  38. 38.
    Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis. 1999;34(3):486–92.CrossRefPubMedGoogle Scholar
  39. 39.
    Messer J, Mulcahy B, Fissell WH. Middle-molecule clearance in CRRT: in vitro convection, diffusion and dialyzer area. ASAIO J. 2009;55(3):224–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Kumar VA, Craig M, Depner TA, Yeun JY. Extended daily dialysis: a new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis. 2000;36(2):294–300.CrossRefPubMedGoogle Scholar
  41. 41.
    Zaccaria R, Ronco C. Dose and efficiency of renal replacement therapy: continuous renal replacement therapy versus intermittent hemodialysis versus slow extended daily dialysis. Cril Care Med. 2008;36 Suppl 4.Google Scholar
  42. 42.
    Marshall M, Ma T, Galler D, et al. Sustained low-efficiency daily diafiltration for critically ill patients requiring renal replacement therapy: towards an adequate therapy. Nephrol Dail Transplant. 2004;19:877–84.Google Scholar
  43. 43.
    Vanholder R, Biesen WV, Lameire N. What is the renal replacement method of first choice for intensive care patients? J Am Soc Nephrol. 2001;12:S40–3.PubMedGoogle Scholar
  44. 44.
    Ronco C, Bellomo R. New CRRT systems: impact on dose delivery. Am J Kidney Dis. 1997;30(5 Suppl 4):S15–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Alarabi AA, Danielson BG, Wikström B. Continuous arteriovenous hemodialysis: outcome in intensive care acute renal failure patients. Nephron. 1993;64(1):58–62.CrossRefPubMedGoogle Scholar
  46. 46.
    Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten H, Ronco C, Kellum JA. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med. 2007;33(9):1563–70.Google Scholar
  47. 47.
    Tolwani AJ, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dial. 2009;22(2):141–5.CrossRefPubMedGoogle Scholar
  48. 48.
    Sagedal S, Hartmann A. Low molecular weight heparins as thromboprophylaxis in patients undergoing hemodialysis/hemofiltration or continuous renal replacement therapies. Eur J Med Res. 2004;9(3):125–30.PubMedGoogle Scholar
  49. 49.
    Oudemans-van Straaten HM, Wester JP, de Pont AC, Schetz MR. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med. 2006;32(2):188–202.CrossRefPubMedGoogle Scholar
  50. 50.
    Gainza FJ, Quintanilla N, Pijoan JI, Delgado S, Urbizu JM, Lampreabe I. Role of prostacyclin (epoprostenol) as anticoagulant in continuous renal replacement therapies: efficacy, security and cost analysis. J Nephrol. 2006;19(5):648–55.PubMedGoogle Scholar
  51. 51.
    Birnbaum J, Spies CD, Klotz E, Hein OV, Morgera S, Schink T, Ziemer S, Grund MS, Saalmann R, Kox WJ, Lehmann C. Iloprost for additional anticoagulation in continuous renal replacement therapy—a pilot study. Ren Fail. 2007;29(3):271–7.CrossRefPubMedGoogle Scholar
  52. 52.
    Vargas Hein O, von Heymann C, Lipps M, Ziemer S, Ronco C, Neumayer HH, Morgera S, Welte M, Kox WJ, Spies C. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med. 2001;27(4):673–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Link A, Girndt M, Selejan S, Mathes A, Böhm M, Rensing H. Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med. 2009;37(1):105–10.CrossRefPubMedGoogle Scholar
  54. 54.
    de Pont AC, Bouman CS, de Jonge E, Vroom MB, Büller HR, Levi M. Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis. Intensive Care Med. 2003;29(7):1205.CrossRefPubMedGoogle Scholar
  55. 55.
    Amanzadeh J, Reilly RF. Anticoagulation and continuous renal replacement therapy. Semin Dial. 2006;19(4):311–6.CrossRefPubMedGoogle Scholar
  56. 56.
    Joannidis M, Oudemans-van Straaten HM. Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care. 2007;11(4):218.CrossRefPubMedGoogle Scholar
  57. 57.
    Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int. 1999;55(5):1991–7.CrossRefPubMedGoogle Scholar
  58. 58.
    Burry LD, Tung DD, Hallett D, Bailie T, Carvalhana V, Lee D, Ramganesh S, Richardson R, Mehta S, Lapinsky SE. Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy. Ann Pharmacother. 2009;43(9):1419–25.CrossRefPubMedGoogle Scholar
  59. 59.
    Davies H, Leslie G. Maintaining the CRRT circuit: non-anticoagulant alternatives. Aust Crit Care. 2006;19(4):133–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Mehta RL. Anticoagulation during continuous renal replacement therapy. ASAIO J. 1994;40(4):931–5.PubMedGoogle Scholar
  61. 61.
    Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med. 2000;26(11):1652–7.CrossRefPubMedGoogle Scholar
  62. 62.
    Morabito S, Pierucci A, Marinelli R, Cicciarelli A, Guzzo I, Cinotti GA, Marino B, Chiavarelli R. Efficiency of different hollow-fiber hemofilters in continuous arteriovenous hemodiafiltration. Am J Nephrol. 2000;20(2):116–21.CrossRefPubMedGoogle Scholar
  63. 63.
    Isla A, Gascón AR, Maynar J, Arzuaga A, Sánchez-Izquierdo JA, Pedraz JL. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies. Chemotherapy. 2007;53(3):194–201.CrossRefPubMedGoogle Scholar
  64. 64.
    Leypoldt JK, Gilson JF, Blindauer KM, Cheung AK. Macromolecule adsorption to hemodialysis membranes depends on molecular size. Blood Purif. 1992;10(1):53–60.CrossRefPubMedGoogle Scholar
  65. 65.
    Bouman CS, van Olden RW, Stoutenbeek CP. Cytokine filtration and adsorption during pre- and postdilution hemofiltration in four different membranes. Blood Purif. 1998;16(5):261–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Pritesh Patel
    • 1
  • Veena Nandwani
    • 1
  • Paul J. McCarthy
    • 1
    • 2
  • Steven A. Conrad
    • 1
    • 2
  • L. Keith Scott
    • 1
    • 2
  1. 1.Department of MedicineLouisiana State University Health Sciences CenterShreveportUSA
  2. 2.Department of NeurosurgeryLouisiana State University Health Sciences CenterShreveportUSA

Personalised recommendations